S-1/A: Nuwellis, Inc. Launches Public Offering Amidst Going Concern Doubts and Nasdaq Compliance Challenges

Nuwellis, Inc., a medical technology company, is launching a public offering of common stock and warrants to raise approximately $4.2 million for working capital and potential acquisition activities, while facing significant financial challenges including accumulated deficits and ongoing Nasdaq listing compliance issues.

Summary

• Nuwellis, Inc. is offering 5,387,931 shares of common stock, Series A Warrants to purchase up to 16,163,793 shares, and Series B Warrants to purchase up to 5,387,931 shares, at an assumed combined public offering price of $0.928 per share.
• The offering also includes pre-funded warrants to purchase up to 5,387,931 shares of common stock, with an exercise price of $0.0001 per share, which will not generate significant additional funds upon exercise.
• The company expects to raise approximately $4.2 million in net proceeds from this offering, or $4.9 million if the underwriters' over-allotment option is fully exercised.
• Proceeds are intended for working capital and general corporate purposes, including potential acquisition activity, specifically mentioning a possible bid for Arch Therapeutics, Inc.'s assets.
• Nuwellis reported a net loss of $3.0 million for the three months ended March 31, 2025, and an accumulated deficit of $301.8 million as of the same date.
• The company's financial statements include an explanatory paragraph raising substantial doubt about its ability to continue as a going concern through the next twelve months.
• Nuwellis has identified a material weakness in its internal control over financial reporting due to insufficient headcount for adequate segregation of duties and lack of contemporaneous documentation for control implementation.
• The company faces ongoing Nasdaq listing compliance issues, having received notices for failing to meet the minimum bid price and minimum stockholders' equity requirements, and is currently under a Mandatory Panel Monitor for one year.
• A 1-for-35 reverse stock split was effected on June 27, 2024, which could negatively impact Nasdaq listing under new rules for companies with cumulative reverse stock splits of one for 250 or more shares over two years.
• The common warrants will not be exercisable until stockholder approval is obtained, and the company has committed to holding meetings every 40 days until such approval is secured, incurring substantial costs and management attention.
• The company voluntarily recalled specific lots of the AquaFlexFlow UF 500 Plus extracorporeal blood circuit on December 11, 2024, due to 'Ultrafiltrate Weight Mismatch' or 'Excessive Weight Mismatch' alarms, with three reported incidents leading to patient dehydration, resulting in a Class 1 recall by the FDA.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to the company's 'going concern' doubt, persistent operating losses, significant accumulated deficit, and ongoing Nasdaq listing challenges. While the capital raise provides a temporary lifeline, its highly dilutive nature and the lack of immediate cash proceeds from certain warrants are concerning. The recent Class 1 product recall further adds to the negative outlook, highlighting operational and quality control risks. The potential acquisition of Arch Therapeutics' assets is a positive strategic move, but its success is uncertain and contingent on the capital raise.

Positives

• The public offering aims to raise approximately $4.2 million in net proceeds, providing much-needed working capital and funds for general corporate purposes.
• The company is actively pursuing strategic growth opportunities, including considering a bid for substantially all the assets of Arch Therapeutics, Inc., a biotechnology company with regulatory authorization for wound care products.
• Nuwellis's Aquadex SmartFlow system received 510(k) clearance in February 2020 to include pediatric patients weighing 20kg or more, expanding its commercialization efforts.
• A new dedicated Category III CPT code (0692T) for Therapeutic Ultrafiltration became effective on January 1, 2022, providing additional reimbursement for outpatient use of the Aquadex system.
• The company has regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements, although it remains under a one-year mandatory panel monitor.

Negatives

• Nuwellis has incurred operating losses since its inception, including a net loss of $3.0 million for the three months ended March 31, 2025, and has an accumulated deficit of $301.8 million.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern through the next twelve months, indicating severe liquidity concerns.
• A material weakness in internal control over financial reporting has been identified due to insufficient headcount and lack of documentation, posing risks to financial statement accuracy and reputation.
• The company's near-term prospects are highly dependent on revenue from a single product, the Aquadex System, and it faces significant challenges in expanding market acceptance.
• Dependence on a limited number of customers (top 10 customers accounted for 57.9% of Q1 2025 revenue) makes the company vulnerable to revenue declines if these customers reduce purchases.
• The offering includes highly dilutive warrants (Series A, Series B, and Representative Warrants), and the common warrants require stockholder approval to be exercisable, with no guarantee of obtaining it, potentially rendering them valueless.
• The Series B Warrants include a zero cash exercise option, meaning the company will likely not receive additional funds upon their exercise.
• The company has limited commercial manufacturing experience and relies on third-party and single-source suppliers, making it vulnerable to supply problems and price fluctuations.
• A voluntary Class 1 recall of the AquaFlexFlow UF 500 Plus extracorporeal blood circuit occurred in December 2024 due to product failures leading to patient dehydration, which could result in significant costs, negative publicity, and product liability claims.
• The dilutive nature of the offering may cause the stock price to fall below Nasdaq's minimum bid price, potentially leading to delisting for public interest concerns.

Risks

• The company's ability to continue as a going concern is in substantial doubt, requiring additional capital that may not be available on favorable terms or at all.
• Failure to remediate the identified material weakness in internal control over financial reporting could adversely affect business, reputation, and stock price.
• Nasdaq may delist the common stock due to minimum bid price non-compliance, minimum stockholders' equity non-compliance, or public interest concerns related to dilutive warrants, limiting trading ability and access to capital.
• Sales of a substantial number of shares by existing stockholders or upon warrant exercise could cause the stock price to fall due to market dilution.
• Dependence on a limited number of customers and single-source suppliers creates significant vulnerability to revenue and supply chain disruptions.
• Product defects and potential product liability lawsuits, as evidenced by the recent Class 1 recall, could harm the business, financial condition, and reputation.
• Non-compliance with complex and evolving healthcare laws and regulations (e.g., FDA, anti-kickback, false claims, off-label use, data privacy like GDPR) could lead to substantial penalties and operational restrictions.
• International operations expose the company to risks such as exchange rate fluctuations, difficulties in enforcing receivables, political instability, and compliance with foreign regulations like EU MDR.
• Inability to protect intellectual property rights, including expiring patents and challenges to pending applications, could adversely affect business and financial results.
• Security breaches, data loss, and other disruptions to IT systems could compromise sensitive information and expose the company to liability.
• The company's ability to use U.S. net operating loss carryforwards may be limited by Section 382 of the Internal Revenue Code due to past or future ownership changes.
• Anti-takeover provisions in the company's charter documents and Delaware law may delay or deter a change-in-control transaction, potentially limiting stockholder value.
• Unstable global economic and market conditions, including inflation and changes in government spending or trade policies, could adversely affect the business and stock price.

Future Outlook

Nuwellis anticipates continued operating losses in the near-term as it invests in expanding sales and marketing capabilities, manufacturing, and public company compliance. The company's ability to become profitable depends on increasing adoption and market acceptance of the Aquadex System. It plans to use the net proceeds from this offering for working capital and general corporate purposes, including potential acquisition activities like bidding for Arch Therapeutics' assets. The company intends to complete EU MDR certification and CE Mark under MDR prior to the extended deadline of December 31, 2028. Nuwellis will also continue to seek stockholder approval for the exercisability of common warrants, holding meetings every 40 days until approval is obtained.

Management Comments

• "We are a smaller reporting company as defined under U.S. federal securities laws and, as such, have elected to comply with reduced public company reporting requirements."
• "We currently intend to use the net proceeds of this offering for working capital and general corporate purposes, including possible acquisition activity."
• "We will consider submitting a bid for the Arch assets. Even if we do submit a bid, there is no assurance that our bid will be accepted."
• "We believe the Aquadex System may offer hospitals an economic benefit for using the device on a regular basis for in-patient or out-patient usage to avoid readmissions for heart failure."
• "Although we believe that all of our communications regarding off label uses are in compliance with the relevant regulatory requirements, the FDA or another regulatory authority may disagree, and characterize such communications as marketing and promotion of an off label use."
• "The Company is taking steps to remediate these material weaknesses as soon as possible."
• "We will make every reasonable effort to obtain promptly the lifting of such order [stop order or suspension of qualification]."

Industry Context

Nuwellis operates in the highly competitive medical technology sector, specifically focusing on ultrafiltration therapy for fluid overload. Its primary product, the Aquadex System, competes indirectly with pharmacological treatments like diuretics, which are the standard of care. Other device-based competitors include Baxter's Prismaflex and Medtronic's Carpe diem system, though these are indicated for different patient populations or conditions. The industry is heavily regulated by bodies like the FDA and subject to evolving healthcare laws, reimbursement policies, and data privacy regulations (e.g., GDPR, HIPAA). The company's expansion into pediatrics and the establishment of a dedicated CPT code for therapeutic ultrafiltration reflect efforts to broaden market penetration and improve reimbursement, which are key industry trends. The potential acquisition of Arch Therapeutics' assets suggests a strategy to diversify its product portfolio within the medical device space, particularly into wound care and hemostasis, which could offer new revenue streams and reduce reliance on a single product.

Comparison to Industry Standards

• Nuwellis's Aquadex System competes against pharmacological treatments (diuretics) as the standard of care for fluid overload, requiring the company to demonstrate superior safety, efficacy, ease-of-use, and cost-effectiveness compared to established, often lower-cost, alternatives.
• Indirect device competitors include Baxter's Prismaflex, approved for continuous renal replacement therapy in patients weighing 20kg or more with acute renal failure and/or fluid overload, and Medtronic's Carpe diem system, indicated for acute kidney injury or fluid overloaded pediatric patients requiring hemodialysis or hemofiltration therapy. Nuwellis's Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20kg or more whose fluid overload is unresponsive to medical management, positioning it within a specific niche but facing broader competition for patient care.
• The company's recent Class 1 recall of the AquaFlexFlow UF 500 Plus extracorporeal blood circuit due to 'Ultrafiltrate Weight Mismatch' or 'Excessive Weight Mismatch' alarms, leading to patient dehydration, highlights significant product quality and safety challenges that can impact market trust and regulatory standing, a critical factor in the medical device industry where product reliability is paramount.
• Nuwellis's ongoing Nasdaq listing compliance issues (minimum bid price, stockholders' equity) and the need for a highly dilutive capital raise are indicative of a company struggling to meet financial benchmarks common for publicly traded medical technology firms, especially compared to more established or profitable industry players.
• The company's accumulated deficit of $301.8 million and continued operating losses are significantly below industry standards for sustained profitability and financial health, raising substantial doubt about its ability to continue as a going concern, a red flag for investors compared to financially stable peers.

Management Changes

Corporate Governance

Legal Proceedings

• On December 11, 2024, Nuwellis initiated a voluntary Class 1 recall of specific lots of the AquaFlexFlow UF 500 Plus extracorporeal blood circuit due to failures (Ultrafiltrate Weight Mismatch or Excessive Weight Mismatch alarms) that could result in excess fluid removal from patients, leading to Acute Volume Depletion.
• Five reported incidences of blood circuit product failures were noted, with three leading to patient dehydration and requiring fluid administration.
• The recall was conducted with the knowledge of the U.S. Food and Drug Administration (FDA), which characterized it as a Class 1 recall, indicating a reasonable probability that use of or exposure to a violative product will cause serious adverse health consequences or death.

Related Party Transactions

• Except as disclosed in the Registration Statement, Prospectus, Prospectus Supplement, or SEC Reports, no officers, directors, or employees are party to any transaction with the Company or its Subsidiaries in excess of $120,000, other than for salary, bonus, consulting fees, expense reimbursement, and equity benefits.

Stakeholder Impact

• Shareholders will experience immediate and substantial dilution from the issuance of new common stock and warrants in this offering.
• Shareholders face significant risk of Nasdaq delisting, which could limit liquidity, increase volatility, and make it harder to buy or sell shares.
• Shareholders will not receive cash dividends in the foreseeable future, as the company intends to retain earnings for development and expansion.
• Employees and management may face increased pressure to achieve profitability and remediate internal control weaknesses.
• Customers may be impacted by product recalls, as evidenced by the recent Class 1 recall of the AquaFlexFlow UF 500 Plus extracorporeal blood circuit, which could affect product availability and trust.
• Suppliers, particularly single-source suppliers, are critical to the company's operations, and any disruption could severely impact manufacturing and product delivery.
• Creditors face increased risk due to the company's 'going concern' doubt and accumulated deficit, although the capital raise may provide some short-term relief.
• The company's ability to attract and retain institutional investors may be hampered by its smaller reporting company status and ongoing financial and compliance challenges.

Next Steps

• Nuwellis will use the net proceeds from this offering for working capital and general corporate purposes, including possible acquisition activity.
• The company will consider submitting a bid for substantially all the assets of Arch Therapeutics, Inc. by June 20, 2025, if sufficient funds are raised.
• Nuwellis will hold a meeting to obtain 'Warrant Stockholder Approval' as soon as practicable following the closing of this offering, but no later than sixty days following the closing, and will hold additional meetings every forty days thereafter until approval is obtained.
• Nuwellis intends to complete MDR certification and CE Mark under EU MDR prior to the extended deadline of December 31, 2028.
• The company will continue to take steps to remediate the material weakness in its internal control over financial reporting.
• Nuwellis will continue to actively monitor its performance with respect to Nasdaq listing standards and consider available options to resolve any deficiencies.

Key Dates

Recommendation

Keywords

Nuwellis, Aquadex SmartFlow, Ultrafiltration Therapy, Medical Devices, SEC Filing, S-1/A, Public Offering, Common Stock, Warrants, Pre-Funded Warrants, Nasdaq Listing, Going Concern, Financial Health, Risk Factors, Dilution, Corporate Governance, Product Recall, Healthcare Regulation, Medical Technology, Capital Raise